The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for Phase 1 Ifenprodil small cell lung cancer study

Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) to treat small cell lung cancer.
The Market Herald Video

" Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study

Algernon (AGN) received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study

Algernon Pharmaceuticals (AGN) has established the optimum peak stimulation period for neuron outgrowth by AP-188 (DMT) in its pre-clinical in vitro study.

" Algernon Pharmaceuticals (CSE:AGN) receives $2M payment and applies for Nasdaq listing

Algernon Pharmaceuticals (AGN) has recently received a $2M cash payment from a refundable tax credit program for its clinical research work in Australia.

" Algernon (CSE:AGN) files meeting request with the MHRA for use of DMT in human stroke study

Algernon Pharmaceuticals (AGN) has filed a scientific advice meeting request with the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). 
The Market Herald Video

" Algernon (CSE:AGN) files pre-IND meeting request for phase 2 Ifenprodil chronic cough study

Algernon Pharmaceuticals  (AGN) has filed a pre-IND meeting request with the U.S. Food and Drug Administration.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Dr. Mark Williams to the board

Algernon Pharmaceuticals (AGN) is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) welcomes Harry Bloomfield, QC. as a board director and chairman

Algernon Pharmaceuticals (AGN) has elected Harry Bloomfield as a member and Chairman of the Board of Directors.

" Algernon Pharmaceuticals (CSE:AGN) announces NP-120 (Ifenprodil) research program and appoints Dr. William North as lead consultant

Algernon Pharmaceuticals has initiated an NP-120 (Ifenprodil) small cell lung cancer (SCLC) research program.

" Algernon Pharmaceuticals (CSE:AGN) announces licensing agreement with Dartmouth College

Algernon Pharmaceuticals (AGN) has signed an exclusive licensing agreement with Dartmouth College.